Age-related Macular Degeneration Clinical Trial
Official title:
Improving Care Planning and Well-being in Older Adults With Macular Degeneration
The purpose of this randomized trial is to examine the effectiveness of a psycho-social "Preventive Problem Solving Intervention" on emotional well-being, change in future outlook, and vision functioning in 250 Age-related Macular Degeneration patients 60 and older.
Loss of independence and valued activities places Age-related Macular Degeneration (AMD)
patients at increased risk for depression, anxiety, and disability. Patients' emotional and
behavioral responses to AMD can exacerbate the long-term health threat of the disease and
contribute to preventable health care costs, loss of productivity, and burden to family
members.This is a randomized controlled trial of a psycho-social intervention that addresses
three mental health promotion goals: (1) increase emotional well-being, (2) improve future
outlook, and (3) protect or enhance current and future-oriented functioning.
The trial examines the effects of the PREPSI for 250 AMD patients, 60 and older, regardless
of actual vision acuity. All study participants receive 4 group-based vision education
classes and resource information. Subjects are then randomized to Preventive Problem Solving
Intervention (PREPSI) consisting of 8 sessions with certified problem-solving trainers or to
an Enhanced Attention Control arm.
Assessors blind to treatment condition measure Psychological Well-being immediately
post-intervention (Week 16) and at 6-month follow-up, Change in Future Outlook, including
Preparation for Future Care from baseline to 16 week and 6-month follow-up, and Vision
Functioning at 6 month follow-up. Measures include the Psychological Well-being Scale (Ryff &
Keyes, 1995), the Preparation of Future Care Needs Scale (Sörensen & Pinquart, 2001), and the
National Eye Institute Vision Functioning Questionnaire-25 (Stelmack, Stelmack, & Massof,
2002). The primary hypothesis is that PREPSI participants will report greater Psychological
Well-being and more Preparation for Future Care immediately post-intervention (at 16 weeks)
and at 6-month follow-up.
The PREPSI is a short, standardized modification of problem-solving therapy that trains
participants to identify and clearly define current and future problems, and then generate,
evaluate, choose, and implement solutions. The long-term goal of the investigators research
program is to improve quality of life in late adulthood by conducting basic and translational
research on preventive future planning.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05984927 -
NG101 AAV Gene Therapy in Subjects With Wet Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05536297 -
Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy
|
Phase 3 | |
Recruiting |
NCT04101604 -
Biomarkers of Common Eye Diseases
|
||
Completed |
NCT04005352 -
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
|
Phase 3 | |
Withdrawn |
NCT02873351 -
A Safety and Efficacy Study of Carbidopa-levodopa in Patients With Macular Degeneration
|
Phase 2 | |
Active, not recruiting |
NCT02802657 -
Efficacy and Safety of "Treat-and-Extend" Regimen Versus "Pro Re Nata" of Conbercept in Age-related Macular Degeneration
|
Phase 4 | |
Not yet recruiting |
NCT02864472 -
Comparison of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV With Initial Loading Dose
|
Phase 4 | |
Recruiting |
NCT01521065 -
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
|
Phase 2 | |
Completed |
NCT01445548 -
Sirolimus for Advanced Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02035722 -
Intravitreal Injections-related Anxiety
|
Phase 2/Phase 3 | |
Completed |
NCT01175395 -
20089 TA+Lucentis Combo Intravitreal Injections for Treatment of Neovascular Age-related Macular Degeneration (AMD)
|
Phase 1/Phase 2 | |
Recruiting |
NCT01048476 -
Effects of Lutein and Zeaxanthin Supplementation on Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01174407 -
Implication of CD35, CD21 and CD55 in Exudative Age-related Macular Degeneration
|
N/A | |
Terminated |
NCT00712491 -
Phase 1/2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT00345176 -
Age-Related Eye Disease Study 2 (AREDS2)
|
Phase 3 | |
Completed |
NCT02140151 -
Prophylactic Ranibizumab for Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Completed |
NCT02555306 -
A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration
|
Phase 1/Phase 2 | |
Recruiting |
NCT04796545 -
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
|
N/A | |
Completed |
NCT03166202 -
Age-Related Macular Degeneration, Scotopic Dysfunction, and Driving Performance in a Simulator
|
||
Completed |
NCT01397409 -
Evaluation of AGN-150998 in Exudative Age-related Macular Degeneration (AMD)
|
Phase 2 |